JP2010138190A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010138190A5 JP2010138190A5 JP2010049998A JP2010049998A JP2010138190A5 JP 2010138190 A5 JP2010138190 A5 JP 2010138190A5 JP 2010049998 A JP2010049998 A JP 2010049998A JP 2010049998 A JP2010049998 A JP 2010049998A JP 2010138190 A5 JP2010138190 A5 JP 2010138190A5
- Authority
- JP
- Japan
- Prior art keywords
- thioxanthine
- alkyl
- formula
- compound
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 12
- 125000000217 alkyl group Chemical group 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 9
- 239000011780 sodium chloride Substances 0.000 claims 9
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 6
- 229910052717 sulfur Inorganic materials 0.000 claims 6
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- RSPDBEVKURKEII-UHFFFAOYSA-N 3-(oxolan-2-ylmethyl)-2-sulfanylidene-7H-purin-6-one Chemical compound C1=2N=CNC=2C(=O)NC(=S)N1CC1CCCO1 RSPDBEVKURKEII-UHFFFAOYSA-N 0.000 claims 3
- BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 229910052727 yttrium Inorganic materials 0.000 claims 3
- 239000002671 adjuvant Substances 0.000 claims 2
- 230000000240 adjuvant Effects 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 2
- 239000000969 carrier Substances 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 125000005842 heteroatoms Chemical group 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000002314 neuroinflammatory Effects 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- BZKMVNIULPWSQZ-UHFFFAOYSA-N 1,3-dibutyl-8-methyl-6-sulfanylidene-7H-purin-2-one Chemical compound S=C1N(CCCC)C(=O)N(CCCC)C2=C1NC(C)=N2 BZKMVNIULPWSQZ-UHFFFAOYSA-N 0.000 claims 1
- SGKJJXCTYVZODW-UHFFFAOYSA-N 1,8-dimethyl-3-(2-methylpropyl)-6-sulfanylidene-7H-purin-2-one Chemical compound S=C1N(C)C(=O)N(CC(C)C)C2=C1NC(C)=N2 SGKJJXCTYVZODW-UHFFFAOYSA-N 0.000 claims 1
- SWTXSGKQNZRCQK-UHFFFAOYSA-N 1-methyl-3-(2-methylpropyl)-2-sulfanylidene-7H-purin-6-one Chemical compound O=C1N(C)C(=S)N(CC(C)C)C2=C1NC=N2 SWTXSGKQNZRCQK-UHFFFAOYSA-N 0.000 claims 1
- VXTADZREIUKIHH-UHFFFAOYSA-N 3-(2-methoxyethyl)-2-sulfanylidene-7H-purin-6-one Chemical compound O=C1NC(=S)N(CCOC)C2=C1NC=N2 VXTADZREIUKIHH-UHFFFAOYSA-N 0.000 claims 1
- YWXBNZQTOMKSGH-UHFFFAOYSA-N 3-(2-methylbutyl)-6-sulfanylidene-7H-purin-2-one Chemical compound S=C1NC(=O)N(CC(C)CC)C2=C1NC=N2 YWXBNZQTOMKSGH-UHFFFAOYSA-N 0.000 claims 1
- HWSAZERBFFRQGX-UHFFFAOYSA-N 3-(2-methylpropyl)-2-sulfanylidene-7H-purin-6-one Chemical compound O=C1NC(=S)N(CC(C)C)C2=C1NC=N2 HWSAZERBFFRQGX-UHFFFAOYSA-N 0.000 claims 1
- KDGNPNTWFNHLSX-UHFFFAOYSA-N 3-(2-methylpropyl)-7H-purine-2,6-dithione Chemical compound S=C1NC(=S)N(CC(C)C)C2=C1NC=N2 KDGNPNTWFNHLSX-UHFFFAOYSA-N 0.000 claims 1
- QYMIGFAAZFXYSQ-UHFFFAOYSA-N 3-(2-phenylethyl)-2-sulfanylidene-7H-purin-6-one Chemical compound C1=2N=CNC=2C(=O)NC(=S)N1CCC1=CC=CC=C1 QYMIGFAAZFXYSQ-UHFFFAOYSA-N 0.000 claims 1
- BYEFLNKUKSUKMO-UHFFFAOYSA-N 3-(3-methoxypropyl)-2-sulfanylidene-7H-purin-6-one Chemical compound O=C1NC(=S)N(CCCOC)C2=C1NC=N2 BYEFLNKUKSUKMO-UHFFFAOYSA-N 0.000 claims 1
- QTXZVSXYBGMMAU-UHFFFAOYSA-N 3-(cyclohexylmethyl)-2-sulfanylidene-7H-purin-6-one Chemical compound C1=2N=CNC=2C(=O)NC(=S)N1CC1CCCCC1 QTXZVSXYBGMMAU-UHFFFAOYSA-N 0.000 claims 1
- KULKOCNEGWFYNO-UHFFFAOYSA-N 3-(cyclopropylmethyl)-2-sulfanylidene-7H-purin-6-one Chemical compound C1=2N=CNC=2C(=O)NC(=S)N1CC1CC1 KULKOCNEGWFYNO-UHFFFAOYSA-N 0.000 claims 1
- XGZKFMGVJXEFAS-UHFFFAOYSA-N 3-(furan-2-ylmethyl)-2-sulfanylidene-7H-purin-6-one Chemical compound C1=2N=CNC=2C(=O)NC(=S)N1CC1=CC=CO1 XGZKFMGVJXEFAS-UHFFFAOYSA-N 0.000 claims 1
- GMNQNGTVFNOHLD-UHFFFAOYSA-N 3-[(4-fluorophenyl)methyl]-2-sulfanylidene-7H-purin-6-one Chemical compound C1=CC(F)=CC=C1CN1C(=S)NC(=O)C2=C1N=CN2 GMNQNGTVFNOHLD-UHFFFAOYSA-N 0.000 claims 1
- HZXVQEUOCFTRDT-UHFFFAOYSA-N 3-[(4-methoxyphenyl)methyl]-2-sulfanylidene-7H-purin-6-one Chemical compound C1=CC(OC)=CC=C1CN1C(=S)NC(=O)C2=C1N=CN2 HZXVQEUOCFTRDT-UHFFFAOYSA-N 0.000 claims 1
- PMCJHNWKVBFKTN-UHFFFAOYSA-N 3-butyl-2-sulfanylidene-7H-purin-6-one Chemical compound O=C1NC(=S)N(CCCC)C2=C1NC=N2 PMCJHNWKVBFKTN-UHFFFAOYSA-N 0.000 claims 1
- OPZUKVWMKYAGPB-UHFFFAOYSA-N 7-methyl-3-(2-methylpropyl)-2-sulfanylidenepurin-6-one Chemical compound O=C1NC(=S)N(CC(C)C)C2=C1N(C)C=N2 OPZUKVWMKYAGPB-UHFFFAOYSA-N 0.000 claims 1
- NKEZZQHUMGOMGY-UHFFFAOYSA-N 8-methyl-1,3-bis(2-methylpropyl)-6-sulfanylidene-7H-purin-2-one Chemical compound S=C1N(CC(C)C)C(=O)N(CC(C)C)C2=C1NC(C)=N2 NKEZZQHUMGOMGY-UHFFFAOYSA-N 0.000 claims 1
- WLSCEYDWCKJQSG-UHFFFAOYSA-N 8-methyl-3-(2-methylpropyl)-2-sulfanylidene-7H-purin-6-one Chemical compound O=C1NC(=S)N(CC(C)C)C2=C1NC(C)=N2 WLSCEYDWCKJQSG-UHFFFAOYSA-N 0.000 claims 1
- IXHYELJKKHRULV-UHFFFAOYSA-N 8-methyl-3-(2-methylpropyl)-6-sulfanylidene-7H-purin-2-one Chemical compound S=C1NC(=O)N(CC(C)C)C2=C1NC(C)=N2 IXHYELJKKHRULV-UHFFFAOYSA-N 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- CFHGBZLNZZVTAY-UHFFFAOYSA-N Lawesson's reagent Chemical compound C1=CC(OC)=CC=C1P1(=S)SP(=S)(C=2C=CC(OC)=CC=2)S1 CFHGBZLNZZVTAY-UHFFFAOYSA-N 0.000 claims 1
- CYQAYERJWZKYML-UHFFFAOYSA-N Phosphorus pentasulfide Chemical compound S1P(S2)(=S)SP3(=S)SP1(=S)SP2(=S)S3 CYQAYERJWZKYML-UHFFFAOYSA-N 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 230000000875 corresponding Effects 0.000 claims 1
- 150000004985 diamines Chemical class 0.000 claims 1
- 235000019253 formic acid Nutrition 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 125000005113 hydroxyalkoxy group Chemical group 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000003287 optical Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
Claims (13)
- 式(Ia)もしくは(Ib)
XおよびYの1つはSを表し、そして他はOまたはSを表し、
R1は、水素またはC1〜6アルキルを表し、
R2は、水素またはC1〜6アルキルを表し、該アルキル基は、
i)O、NおよびSから独立して選ばれる1つもしくは2つのヘテロ原子を場合により含み、そして1つのカルボニル基を場合により含む、飽和もしくは部分的に不飽和の3〜7員環;ここで、該環はハロゲン、ヒドロキシ、C1〜6アルコキシおよびC1〜6アルキルから選ばれる1つもしくは2つ以上の置換基によって場合により置換され、該アルキルはヒドロキシもしくはC1〜6アルコキシによって場合によりさらに置換される、またはii)C1〜6アルコキシ、または
iii)フェニル、フリルもしくはチエニルから選ばれる芳香環;ここで、該芳香環はハロ
ゲン、C1〜6アルキルもしくはC1〜6アルコキシによって場合によりさらに置換される、
によって場合により置換され、
R3およびR4は、独立して水素またはC1〜6アルキルを表す)
の化合物または薬学的に許容し得るその塩の、酵素MPOの阻害が有益である疾患もしくは症状の治療もしくは予防のための薬剤の製造における使用。 - 疾患または症状が神経性炎症障害である請求項1に記載の使用。
- XがSを表しそしてYがOを表す、請求項1または2に記載の使用。
- R3がHを表す、請求項1〜3のいずれか1項に記載の使用。
- R2が場合により置換されたC1〜6アルキルを表す、請求項1〜4のいずれか1項に
記載の使用。 - R4がHを表す、請求項1〜5のいずれか1項に記載の使用。
- 神経性炎症障害の治療または予防に使用するための請求項1記載の式(Ia)もしくは(Ib)の化合物または薬学的に許容し得るその塩の治療的に有効な量を、薬学的に許容し得る補助剤、希釈剤または担体と混合して含有する医薬製剤。
- 式(Ia)もしくは(Ib)
XはSを表し、そしてYはOを表し、
R1は、水素またはC1〜6アルキルを表し、
R2は、O、NおよびSから独立して選ばれる1つまたは2つのヘテロ原子を場合によ
り含み、そして1つのカルボニル基を場合により含む飽和または部分的に不飽和の3〜7員環によって置換されたC1〜6アルキルを表し、該環はハロゲン、ヒドロキシ、C1〜6アルコキシおよびC1〜6アルキルから選ばれる1つまたは2つ以上の置換基によって場合により置換され、該アルキルはヒドロキシまたはC1〜6アルコキシによって場合によりさらに置換され、
R3およびR4は、独立して水素またはC1〜6アルキルを表す)
の化合物または薬学的に許容し得るその塩。 - 式(Ia)もしくは(Ib)が
1,3−ジイソブチル−8−メチル−6−チオキサンチン、
1,3−ジブチル−8−メチル−6−チオキサンチン、
3−イソブチル−1,8−ジメチル−6−チオキサンチン、
3−(2−メチルブチル)−6−チオキサンチン、
3−イソブチル−8−メチル−6−チオキサンチン、
3−イソブチル−2−チオキサンチン、
3−イソブチル−2,6−ジチオキサンチン、
3−イソブチル−8−メチル−2−チオキサンチン、
3−イソブチル−7−メチル−2−チオキサンチン、
3−シクロヘキシルメチル−2−チオキサンチン、
3−(3−メトキシプロピル)−2−チオキサンチン、
3−シクロプロピルメチル−2−チオキサンチン、
3−イソブチル−1−メチル−2−チオキサンチン、
3−(2−テトラヒドロフリル−メチル)−2−チオキサンチン、
3−(2−メトキシ−エチル)−2−チオキサンチン、
3−(3−(1−モルホリニル)−プロピル)−2−チオキサンチン、
3−(2−フリル−メチル)−2−チオキサンチン、
3−(4−メトキシベンジル)−2−チオキサンチン、
3−(4−フルオロベンジル)−2−チオキサンチン、
3−フェネチル−2−チオキサンチン、
(+)−3−(2−テトラヒドロフリル−メチル)−2−チオキサンチン、
(−)−3−(2−テトラヒドロフリル−メチル)−2−チオキサンチン、
3−n−ブチル−2−チオキサンチン
である化合物または薬学的に許容し得るその塩。 - 請求項8または9に記載の化合物の薬剤としての使用。
- 請求項8または9に記載の式(Ia)もしくは(Ib)の化合物もしくは薬学的に許容し得るその塩を、薬学的に許容し得る補助剤、希釈剤もしくは担体と混合して含有する医薬組成物。
- (a)式(IIa)もしくは(IIb)
(b)式(IIIa)もしくは(IIIb)
もしくはトリアルキルオルトエステルと反応させ、
そして必要な場合には、生成した式(Ia)もしくは(Ib)の化合物または他のその塩を薬学的に許容し得るその塩に変換するか、または生成した式(Ia)もしくは(Ib)の化合物を式(Ia)もしくは(Ib)のさらなる化合物に変換し、そして望ましい場
合には生成した式(Ia)または(Ib)の化合物をその光学異性体に変換する
ことを含む、請求項8または9に定義した式(Ia)もしくは(Ib)の化合物または薬学的に許容し得るその塩、鏡像体、ジアステレオマーもしくはラセミ化合物を製造する方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0201193A SE0201193D0 (sv) | 2002-04-19 | 2002-04-19 | Novel use |
SE0202239A SE0202239D0 (sv) | 2002-07-17 | 2002-07-17 | Novel use |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003586151A Division JP4649112B2 (ja) | 2002-04-19 | 2003-04-15 | ミエロペルオキシダーゼ阻害剤としてのチオキサンチン誘導体 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2010138190A JP2010138190A (ja) | 2010-06-24 |
JP2010138190A5 true JP2010138190A5 (ja) | 2010-10-07 |
Family
ID=29253791
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003586151A Expired - Fee Related JP4649112B2 (ja) | 2002-04-19 | 2003-04-15 | ミエロペルオキシダーゼ阻害剤としてのチオキサンチン誘導体 |
JP2010049998A Pending JP2010138190A (ja) | 2002-04-19 | 2010-03-08 | ミエロペルオキシダーゼ阻害剤としてのチオキサンチン誘導体 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003586151A Expired - Fee Related JP4649112B2 (ja) | 2002-04-19 | 2003-04-15 | ミエロペルオキシダーゼ阻害剤としてのチオキサンチン誘導体 |
Country Status (22)
Country | Link |
---|---|
US (2) | US7425560B2 (ja) |
EP (2) | EP1499613B1 (ja) |
JP (2) | JP4649112B2 (ja) |
KR (3) | KR20110132635A (ja) |
CN (1) | CN100379737C (ja) |
AR (1) | AR039385A1 (ja) |
AT (1) | ATE529428T1 (ja) |
AU (2) | AU2003224548B2 (ja) |
BR (1) | BR0309012A (ja) |
CA (2) | CA2480452C (ja) |
ES (1) | ES2373224T3 (ja) |
HK (2) | HK1071568A1 (ja) |
IL (1) | IL164315A0 (ja) |
IS (1) | IS7509A (ja) |
MX (1) | MXPA04010055A (ja) |
MY (1) | MY157949A (ja) |
NO (2) | NO331002B1 (ja) |
NZ (1) | NZ535406A (ja) |
PL (1) | PL373197A1 (ja) |
RU (2) | RU2323219C2 (ja) |
TW (1) | TWI335918B (ja) |
WO (1) | WO2003089430A1 (ja) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR039385A1 (es) * | 2002-04-19 | 2005-02-16 | Astrazeneca Ab | Derivados de tioxantina como inhibidores de la mieloperoxidasa |
SE0302756D0 (sv) * | 2003-10-17 | 2003-10-17 | Astrazeneca Ab | Novel Compounds |
SE0402591D0 (sv) * | 2004-10-25 | 2004-10-25 | Astrazeneca Ab | Novel use |
MY140748A (en) * | 2004-12-06 | 2010-01-15 | Astrazeneca Ab | Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy |
TW200806667A (en) * | 2006-04-13 | 2008-02-01 | Astrazeneca Ab | New compounds |
WO2007120097A1 (en) * | 2006-04-13 | 2007-10-25 | Astrazeneca Ab | Thioxanthine derivatives and their use as inhibitors of mpo |
TW200804383A (en) * | 2006-06-05 | 2008-01-16 | Astrazeneca Ab | New compounds |
WO2007142577A1 (en) * | 2006-06-05 | 2007-12-13 | Astrazeneca Ab | Pyrrolo[3,2-d]pyrimidin-4-one derivative as myeloperoxidase inhibitor |
AR066936A1 (es) * | 2007-06-13 | 2009-09-23 | Astrazeneca Ab | 3 - (2r - tetrahidrofuril - metil) - 2 - tioxantina. composiciones farmaceuticas. |
US20090054468A1 (en) * | 2007-08-23 | 2009-02-26 | Astrazeneca Ab | New Use 938 |
US20090053176A1 (en) * | 2007-08-23 | 2009-02-26 | Astrazeneca Ab | New Combination 937 |
US20100081159A1 (en) * | 2008-09-26 | 2010-04-01 | Lebedeva Irina V | Profiling reactive oxygen, nitrogen and halogen species |
WO2010062787A1 (en) * | 2008-11-03 | 2010-06-03 | Washington University | Bioluminescence imaging of myeloperoxidase activity in vivo, methods, compositions and apparatuses therefor |
WO2010068171A1 (en) * | 2008-12-12 | 2010-06-17 | Astrazeneca Ab | A process for the preparation of 3- [ (2r) tetrahydrofuran-2- ylmethyl] -2-thioxo-l, 2, 3, 7-tetrahydro-6h-purin-6-one |
US20120122948A1 (en) * | 2009-05-27 | 2012-05-17 | Universite Libre De Beuxelles | 3-alkyl-5-fluoroindole derivatives as myeloperoxidase inhibitors |
GB0913345D0 (en) | 2009-07-31 | 2009-09-16 | Astrazeneca Ab | New combination 802 |
WO2011061527A1 (en) | 2009-11-17 | 2011-05-26 | Astrazeneca Ab | Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases |
WO2011133581A1 (en) | 2010-04-19 | 2011-10-27 | General Atomics | Methods and compositions for assaying enzymatic activity of myeloperoxidase in blood samples |
GB201021979D0 (en) | 2010-12-23 | 2011-02-02 | Astrazeneca Ab | New compound |
GB201021992D0 (en) | 2010-12-23 | 2011-02-02 | Astrazeneca Ab | Compound |
US8765126B2 (en) * | 2011-05-05 | 2014-07-01 | Robert Sackstein | Methods of treating complications and disorders associated with G-CSF administration |
EA027324B1 (ru) | 2011-11-11 | 2017-07-31 | Пфайзер Инк. | 2-тиопиримидиноны |
US9616063B2 (en) | 2014-12-01 | 2017-04-11 | Astrazeneca Ab | 1-[2-(aminomethyl)benzyl]-2-thioxo-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-ones as inhibitors of myeloperoxidase |
PE20180503A1 (es) | 2015-05-05 | 2018-03-09 | Pfizer | 2-tiopirimidinonas |
EP3397640B1 (en) * | 2015-12-29 | 2021-08-04 | INSERM - Institut National de la Santé et de la Recherche Médicale | Xanthine derivative inhibitors of bet proteins |
WO2020021300A1 (en) | 2018-07-24 | 2020-01-30 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of myeloperoxidase (mpo) inhibitors for the treatment of chemoresistant acute myeloid leukemia (aml) |
WO2021013942A1 (en) | 2019-07-24 | 2021-01-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of myeloperoxidase inhibitors for the treatment of cardiovascular diseases in patients suffering from myeloproliferative neoplasms |
US20240166642A1 (en) | 2022-08-18 | 2024-05-23 | Astrazeneca Ab | Inhibitors of myeloperoxidase |
Family Cites Families (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3135753A (en) * | 1961-05-10 | 1964-06-02 | Burroughs Wellcome Co | Alkylthiopurines and method |
SE7810947L (sv) | 1978-10-20 | 1980-04-21 | Draco Ab | 3-alkylxanthines |
US4710503A (en) * | 1985-02-07 | 1987-12-01 | Euroceltique S.A. | 6-thioxanthine derivatives |
AU2948189A (en) | 1987-12-31 | 1989-08-01 | Smithkline Beckman Corporation | 4-aralkyl-5-substituted-1,2,4-triazole-5-thiols |
DK440989A (da) | 1988-09-12 | 1990-03-13 | Smithkline Beecham Corp | Dopamin-beta-hydroxylase inhibitorer |
JPH02160235A (ja) | 1988-12-13 | 1990-06-20 | Konica Corp | ハロゲン化銀カラー写真画像の形成方法 |
WO1990012797A1 (en) | 1989-04-19 | 1990-11-01 | The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce | Sulfer-containing xanthine derivatives as adenosin antagonists |
GB8918297D0 (en) * | 1989-08-10 | 1989-09-20 | Beecham Group Plc | Novel treatment |
EP0430300A3 (en) | 1989-12-01 | 1992-03-25 | Takeda Chemical Industries, Ltd. | Xanthine derivatives, their production and use |
US5100906A (en) | 1990-04-19 | 1992-03-31 | Merrell Dow Pharmaceuticals Inc. | 5-aryl-4-alkyl-3h-1,2,4-triazole-3-thiones useful as memory enhancers |
FR2665636B1 (fr) * | 1990-08-10 | 1994-10-07 | Adir | Utilisation d'un derive de la trimethyl-1,3,7 xanthine pour le traitement des troubles de la memoire, des troubles intellectuels de la senescence et de la maladie d'alzheimer. |
US6046019A (en) * | 1991-07-09 | 2000-04-04 | Goumeniouk; Alexander P. | Diagnostic kits and methods for making granulocyte cell counts |
US6469017B1 (en) | 1998-01-16 | 2002-10-22 | Cell Therapeutics, Inc. | Method of inhibiting interleukin-12 signaling |
GB9312853D0 (en) | 1993-06-22 | 1993-08-04 | Euro Celtique Sa | Chemical compounds |
EP0730588B1 (en) * | 1993-11-26 | 1997-07-02 | Pfizer Inc. | Isoxazoline compounds as antiinflammatory agents |
US5489598A (en) * | 1994-06-08 | 1996-02-06 | Warner-Lambert Company | Cytoprotection utilizing aryltriazol-3-thiones |
WO1996018400A1 (en) * | 1994-12-13 | 1996-06-20 | Euro-Celtique, S.A. | Trisubstituted thioxanthines |
ATE247655T1 (de) * | 1994-12-13 | 2003-09-15 | Euro Celtique Sa | Dreifachsubstituierte thioxanthine |
US6025361A (en) * | 1994-12-13 | 2000-02-15 | Euro-Celtique, S.A. | Trisubstituted thioxanthines |
AU4527896A (en) * | 1994-12-13 | 1996-07-03 | Euro-Celtique S.A. | Aryl thioxanthines |
US5756511A (en) * | 1995-04-03 | 1998-05-26 | Cell Therapeutics, Inc. | Method for treating symptoms of a neurodegenerative condition |
US6294541B1 (en) * | 1996-06-06 | 2001-09-25 | Euro-Celtique S.A. | Purine derivatives having phosphodiesterase IV inhibition activity |
US5976823A (en) * | 1997-03-19 | 1999-11-02 | Integrated Biomedical Technology, Inc. | Low range total available chlorine test strip |
DE69834500T2 (de) * | 1997-09-05 | 2007-05-03 | Kyowa Hakko Kogyo Co., Ltd. | Xanthinderivative zur behandlung von hirnischämie |
WO1999014204A1 (en) | 1997-09-16 | 1999-03-25 | G.D. Searle & Co. | Substituted 1,2,4-triazoles useful for inhibiting cholesteryl ester transfer protein activity |
AR013669A1 (es) | 1997-10-07 | 2001-01-10 | Smithkline Beecham Corp | Compuestos y metodos |
US6187777B1 (en) | 1998-02-06 | 2001-02-13 | Amgen Inc. | Compounds and methods which modulate feeding behavior and related diseases |
US6319928B1 (en) * | 1998-11-30 | 2001-11-20 | Euro-Celtique, S.A. | Purine derivatives having phosphodiesterase IV inhibition activity |
DZ3019A1 (fr) | 1999-03-01 | 2005-05-20 | Smithkline Beecham Corp | Utilisation d'un inhibiteur de pde4 dans la préparation d'un médicament contre la copd. |
WO2000059449A2 (en) | 1999-04-02 | 2000-10-12 | Euro-Celtique S.A. | Purine derivatives having phosphodiesterase iv inhibition activity |
EP1202628B1 (en) | 1999-08-12 | 2004-10-13 | Euro-Celtique S.A. | Novel hypoxanthine and thiohypoxanthine compounds |
GB2362101A (en) * | 2000-05-12 | 2001-11-14 | Astrazeneca Ab | Treatment of chronic obstructive pulmonary disease |
FR2811989A1 (fr) | 2000-07-18 | 2002-01-25 | Sanofi Synthelabo | Derives de polyfluoroalkytriazole, leur preparation et leur application en therapeutique |
EP1305328A2 (en) | 2000-07-21 | 2003-05-02 | Mark B. Lyles | Materials and methods for binding nucleic acids to surfaces |
FR2819723B1 (fr) * | 2001-01-23 | 2006-11-17 | Arnaud Mainnemare | Composition halogene, son procede de preparation et ses utilisations |
WO2002066447A1 (en) | 2001-02-21 | 2002-08-29 | Ono Pharmaceutical Co., Ltd. | 4h-1,2,4-triazole-3(2h)-thione deratives as sphingomyelinase inhibitors |
SE0103766D0 (sv) * | 2001-11-09 | 2001-11-09 | Astrazeneca Ab | Novel assay |
IL158462A0 (en) | 2001-05-08 | 2004-05-12 | Astrazeneca Ab | An assay for detecting inhibitors of the enzyme myeloperoxidase |
ES2193839B1 (es) * | 2001-06-22 | 2005-02-16 | Almirall Prodesfarma, S.A. | Nuevos derivados de 6-fenildihidropirrolpirimidindiona. |
ES2208063B1 (es) | 2002-04-01 | 2005-10-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de la 4-(pirrolopirimidin-6-il)bencenosulfonamida. |
AR039385A1 (es) * | 2002-04-19 | 2005-02-16 | Astrazeneca Ab | Derivados de tioxantina como inhibidores de la mieloperoxidasa |
SE0301232D0 (sv) | 2003-04-25 | 2003-04-25 | Astrazeneca Ab | Novel use |
SE0302756D0 (sv) * | 2003-10-17 | 2003-10-17 | Astrazeneca Ab | Novel Compounds |
MXPA06004789A (es) | 2003-10-31 | 2006-07-03 | Cv Therapeutics Inc | Antagonistas del receptor de adenosina a2b. |
US7713982B2 (en) | 2004-02-14 | 2010-05-11 | Smithkline Beecham Corporation | Xanthines with HM74A receptor activity |
WO2006045564A1 (en) | 2004-10-22 | 2006-05-04 | Smithkline Beecham Corporation | Xanthine derivatives with hm74a receptor activity |
SE0402591D0 (sv) | 2004-10-25 | 2004-10-25 | Astrazeneca Ab | Novel use |
MY140748A (en) | 2004-12-06 | 2010-01-15 | Astrazeneca Ab | Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy |
TW200806667A (en) * | 2006-04-13 | 2008-02-01 | Astrazeneca Ab | New compounds |
TW200804383A (en) | 2006-06-05 | 2008-01-16 | Astrazeneca Ab | New compounds |
AR066936A1 (es) * | 2007-06-13 | 2009-09-23 | Astrazeneca Ab | 3 - (2r - tetrahidrofuril - metil) - 2 - tioxantina. composiciones farmaceuticas. |
US20090054468A1 (en) * | 2007-08-23 | 2009-02-26 | Astrazeneca Ab | New Use 938 |
-
2003
- 2003-04-07 AR ARP030101208A patent/AR039385A1/es unknown
- 2003-04-14 TW TW092108547A patent/TWI335918B/zh not_active IP Right Cessation
- 2003-04-15 EP EP03721211A patent/EP1499613B1/en not_active Expired - Lifetime
- 2003-04-15 CA CA2480452A patent/CA2480452C/en not_active Expired - Fee Related
- 2003-04-15 KR KR1020117027657A patent/KR20110132635A/ko not_active Application Discontinuation
- 2003-04-15 KR KR1020047016709A patent/KR101064092B1/ko not_active IP Right Cessation
- 2003-04-15 BR BR0309012-4A patent/BR0309012A/pt not_active IP Right Cessation
- 2003-04-15 AU AU2003224548A patent/AU2003224548B2/en not_active Ceased
- 2003-04-15 MX MXPA04010055A patent/MXPA04010055A/es active IP Right Grant
- 2003-04-15 EP EP10170768A patent/EP2332541A1/en not_active Withdrawn
- 2003-04-15 PL PL03373197A patent/PL373197A1/xx not_active Application Discontinuation
- 2003-04-15 KR KR1020117007364A patent/KR20110036871A/ko not_active Application Discontinuation
- 2003-04-15 NZ NZ535406A patent/NZ535406A/en not_active IP Right Cessation
- 2003-04-15 CA CA2752132A patent/CA2752132A1/en not_active Abandoned
- 2003-04-15 AT AT03721211T patent/ATE529428T1/de not_active IP Right Cessation
- 2003-04-15 US US10/511,537 patent/US7425560B2/en not_active Expired - Fee Related
- 2003-04-15 RU RU2004128389/04A patent/RU2323219C2/ru not_active IP Right Cessation
- 2003-04-15 WO PCT/SE2003/000617 patent/WO2003089430A1/en active Application Filing
- 2003-04-15 JP JP2003586151A patent/JP4649112B2/ja not_active Expired - Fee Related
- 2003-04-15 CN CNB038083558A patent/CN100379737C/zh not_active Expired - Fee Related
- 2003-04-15 ES ES03721211T patent/ES2373224T3/es not_active Expired - Lifetime
- 2003-04-17 MY MYPI20031447A patent/MY157949A/en unknown
-
2004
- 2004-09-27 IL IL16431504A patent/IL164315A0/xx unknown
- 2004-10-15 IS IS7509A patent/IS7509A/is unknown
- 2004-11-17 NO NO20044998A patent/NO331002B1/no not_active IP Right Cessation
-
2005
- 2005-05-25 HK HK05104394.9A patent/HK1071568A1/xx unknown
-
2007
- 2007-11-16 RU RU2007142328/04A patent/RU2007142328A/ru not_active Application Discontinuation
-
2008
- 2008-04-18 HK HK08104395.5A patent/HK1114500A1/xx not_active IP Right Cessation
- 2008-08-04 US US12/185,158 patent/US8236951B2/en not_active Expired - Fee Related
-
2010
- 2010-01-29 AU AU2010200345A patent/AU2010200345B2/en not_active Ceased
- 2010-03-08 JP JP2010049998A patent/JP2010138190A/ja active Pending
- 2010-06-28 NO NO20100939A patent/NO20100939L/no not_active Application Discontinuation
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2010138190A5 (ja) | ||
JP2005526836A5 (ja) | ||
RU2004128389A (ru) | Производные тиоксантина в качестве ингибиторов миелопероксидазы | |
JP2009542613A5 (ja) | ||
RU2488582C2 (ru) | Бициклозамещенные азопроизводные пиразолона, способ их получения и фармацевтическое применение | |
JP2017515844A5 (ja) | ||
JP2013032389A5 (ja) | ||
JP2014500861A5 (ja) | ||
JP2011518833A5 (ja) | ||
JP2012505836A5 (ja) | ||
EA201391158A1 (ru) | Диаминиевые соли фенотиазина и их применение | |
JP2010095546A5 (ja) | ||
JP2011529918A5 (ja) | ||
JP2018511647A5 (ja) | ||
WO2009095872A3 (en) | Labelled analogues of halobenzamides as multimodal radiopharmaceuticals and their precursors | |
CA2740484A1 (en) | S1p receptors modulators and their use thereof | |
JP2012532883A5 (ja) | ||
JP2013533253A5 (ja) | ||
JP2013531008A5 (ja) | ||
TW200616634A (en) | Crystalline forms and process for preparing spiro-hydantoin compounds | |
JP2009538910A5 (ja) | ||
JP2015508092A5 (ja) | ||
JP2012513416A5 (ja) | ||
CA2485926A1 (en) | (imidazol-1-yl-methyl)-pyridazine as nmda receptor blocker | |
JP2020500916A5 (ja) |